AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

BOTANIX PHARMACEUTICALS LTD

0.395

+0.0102.60%

Volume:5.38M

Turnover:2.10M

Market Cap:723.93M

PE:-17.00

High:0.400

Open:0.390

Low:0.375

Close:0.385

Loading ...

Overview Company News Filings

ASX Market Close: Bourse rises as Bitcoin breaks a new record | December 17, 2024

The Market Herald

Botanix Says First Prescriptions Issued for Excessive Sweating Treatment Ahead of Q1 Commercial Launch; Shares Down 3%

MT Newswires Live

First Sofdra prescriptions for excessive sweating condition pushes Botanix towards full commercial launch

The Market Herald

The sectors and stocks set for a big 2025

There's more to Australian biotech than just CSL: the opportunities to watch

Here's Why We're Not At All Concerned With Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

Simply Wall St.

5 ways to identify high-quality ASX companies (and 14 stock examples)

Investing in a World of Options and Asymmetry

Botanix Labs' Mission to Bring Bitcoin to Defi Moves to Final Testnet Phase

Those who invested in Botanix Pharmaceuticals (ASX:BOT) three years ago are up 443%

Simply Wall St.

Botanix Pharmaceuticals Says US Payer Group to Cover Its Excessive Sweat Medication; Shares Up 6%

MT Newswires Live

The three-year returns have been enviable for Botanix Pharmaceuticals (ASX:BOT) shareholders despite underlying losses increasing

Simply Wall St.

Botanix Pharmaceuticals on Track to Launch Patient Experience Program for Sofdra in Q4; Shares Up 6%

MT Newswires Live

Here's Why We're Not At All Concerned With Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BOT.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BOT.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BOT.AU\",,,,,undefined,":{"symbol":"BOT.AU","market":"AU","secType":"STK","nameCN":"BOTANIX PHARMACEUTICALS LTD","latestPrice":0.395,"timestamp":1744870320000,"preClose":0.385,"halted":0,"volume":5382654,"delay":0,"nameEN":"BOTANIX PHARMACEUTICALS LTD","floatShares":1589206761,"shares":1832728341,"eps":-0.023239,"marketStatus":"Not Yet Opened","change":0.01,"latestTime":"04-17 16:12:00 AEST","open":0.39,"high":0.4,"low":0.375,"amount":2104364,"amplitude":0.064935,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.023239,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745280000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.385,"openAndCloseTimeList":[[1744848000000,1744869600000]],"volumeRatio":0.6092759240532699,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BOT.AU\",,,,,undefined,":{"symbol":"BOT.AU","floatShares":1589206761,"roa":"-34.36%","roe":"-56.99%","lyrEps":-0.009236,"volumeRatio":0.6092759240532699,"shares":1832728341,"dividePrice":0,"high":0.4,"amplitude":0.064935,"preClose":0.385,"low":0.375,"week52Low":0.21,"pbRate":"7.83","psRate":"349.87","week52High":0.535,"institutionHeld":0,"latestPrice":0.395,"eps":-0.023239,"divideRate":0,"volume":5382654,"delay":0,"ttmEps":-0.023239,"open":0.39,"prevYearClose":0.435,"prevWeekClose":0.395,"prevMonthClose":0.455,"prevQuarterClose":0.455,"fiveDayClose":0.37,"twentyDayClose":0.435,"sixtyDayClose":0.46},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BOT.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2492998646","title":"ASX Market Close: Bourse rises as Bitcoin breaks a new record | December 17, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2492998646","media":"The Market Herald","labels":["economic"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492998646?lang=en_us&edition=fundamental","pubTime":"2024-12-17 14:27","pubTimestamp":1734416820,"startTime":"0","endTime":"0","summary":"With just five trading days ‘til Christmas, the ASX closed up 0.78% at 8,314 points.Bitcoin jumped to an all-time record high above $US107,000 after Donald Trump confirmed plans for a U.S. strategic reserve for the cryptocurrency.The Iron Ore price has risen around half a percent, to US$105.50, dragging the big miners higher, whilst the big banks were the most outstanding players on the market today.Industrials, Real Estate and IT were the best performing sectors, all up around 1.3%, followed by Financials and Health Care, both up 1.1%.Novonix  closed up 3.42% on news the U.S. Department of Energy  hasconditionally committeda direct loan of up to A$1.2 billion to partially finance a proposed new facility in Tennessee.Tamboran Resources  closed up 3.85% after inking a deal with APA Group to deliver the Sturt Plateau Pipeline.Westgold Resources  closed up 4.31% on news of a potential expansion of the Fortnum Gold Operation in the Murchison Region of WA. A scoping study has identified a p","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-close-bourse-rises-as-bitcoin-breaks-a-new-record-december-17-2024-2024-12-17/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"economic","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7096","APA.AU","IDA.AU","BK7084","09042","83042","BK7502","BK7095","NVX.AU","09439","BK7506","BK4588","03439","BOT.AU","TBN.AU","03008","BK4157","BK7142","CGCP","BK4585","BK4594","03042","09008","LM8.AU","NVX","WGX.AU","BK7508","BK1611","BK7104","BK4601","BK7148"],"gpt_icon":1},{"id":"2492067557","title":"Botanix Says First Prescriptions Issued for Excessive Sweating Treatment Ahead of Q1 Commercial Launch; Shares Down 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492067557","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492067557?lang=en_us&edition=fundamental","pubTime":"2024-12-17 08:39","pubTimestamp":1734395992,"startTime":"0","endTime":"0","summary":"Botanix Pharmaceuticals  said the first prescriptions for its Sofdra sofpironium topical gel have been issued via telemedicine and insurance approvals, according to a Tuesday filing with the Australian bourse.Sofdra is approved by the US Food and Drug Administration for the treatment of primary axillary hyperhidrosis, or excessive underarm sweating.The drug is set for full commercial launch in the first quarter of next year, with inventory, infrastructure, and marketing and sales currently advancing, the filing said.The company's shares were down almost 3% in recent Tuesday trade.Price : $0.37, Change: $-0.01, Percent Change: -2.63%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AUD","BOT.AU","LU0994945656.USD","LU0426412945.USD","BK4125","BK7508","LU0345774631.USD","LU2238339852.HKD","BK7502","LU0426417589.USD","LU1043141123.HKD","BK7096"],"gpt_icon":0},{"id":"2492671289","title":"First Sofdra prescriptions for excessive sweating condition pushes Botanix towards full commercial launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2492671289","media":"The Market Herald","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492671289?lang=en_us&edition=fundamental","pubTime":"2024-12-17 07:25","pubTimestamp":1734391500,"startTime":"0","endTime":"0","summary":"Botanix  has reported the first prescriptions of its drug Sofdra  to treat hyperhidrosis, a condition of excessive sweating.According to Botanix, the first prescriptions were quickly followed up by the first deliveries of products to patients; the move was also a confirmation of logistics between Botanix, telehealth partners, and its patients.It’s given Botanix the chance to improve marketing and sales materials, per company statements, with a ‘sales force’ engaged and preparing for a launch meeting in late January.The company ultimately pointed to its transition to a revenue-generating company ahead of the “full commercial launch” in Q1 2025.In the company’s eyes, FDA approval was the gamechanger for the stock. And that’s reflected in the company’s share price. On a 1Y basis, BOT shares are up +153%.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certif","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/first-sofdra-prescriptions-for-excessive-sweating-condition-pushes-botanix-towards-full-commercial-launch-2024-12-17/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BOT.AU","BK7502","BK7096","BK7508"],"gpt_icon":0},{"id":"2491504636","title":"The sectors and stocks set for a big 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2491504636","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491504636?lang=en_us&edition=fundamental","pubTime":"2024-12-16 07:40","pubTimestamp":1734306015,"startTime":"0","endTime":"0","summary":"Recovery to opportunity: Microcaps to benefit from shifting economic winds. 2024 saw a shift in performance for microcap companies after two consecutive years of challenging conditions. The S&P/ASX Emerging Companies Index has returned an impressive 27.88% . However, on a 3-year CAGR basis the index is still recovering, with a -2.40% p.a. return compared to +9.25% p.a. from the ASX 50.Healthcare: Dermatology business Botanix Pharmaceuticals  secured FDA approval for their novel drug to treat hyperhidrosis this year. The commercial launch earmarked for early 2025 will see first sales and prove out the product’s attractive economics. Dimerix  is conducting phase 3 trials for a rare kidney disease, with results expected towards the end of the calendar year. With portfolio holdings radiology business Capitol Health  and dentist franchise Pacific Smi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/the-sectors-and-stocks-set-for-a-big-2025","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/the-sectors-and-stocks-set-for-a-big-2025","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["BK7507","MLX.AU","BK7055","BK7096","DXB.AU","XKO.AU","GDG.AU","BK7016","BK7506","XRF.AU","BK7124","AQZ.AU","BK7113","BK7502","CAJ.AU","BOT.AU","EGH.AU","BK7164","BK7133","RUL.AU","BK7088","BK7501","BK7067","XAO.AU","SND.AU","BK7089","BK7095","AMI.AU","PSQ.AU","BK7508","SXE.AU","BK7030","XJO.AU"],"gpt_icon":0},{"id":"2491503738","title":"There's more to Australian biotech than just CSL: the opportunities to watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2491503738","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491503738?lang=en_us&edition=fundamental","pubTime":"2024-12-16 04:09","pubTimestamp":1734293355,"startTime":"0","endTime":"0","summary":"Just a couple of years ago, CSL stood alone as Australia’s only profitable biotech company. Fast forward to today and the landscape has dramatically shifted, with Neuren and Telix delivering FDA approved products and becoming profitable. Botanix has also recently received FDA approval and is set to launch shortly, further enhancing the sector’s credibility.Several other companies including Opthea , Immutep and Dimerix are progressing through Phase 3 trials, while Syntara is set to potentially begin a Phase 3 trial in 2025, pending feedback from the FDA. The local ecosystem is starting to mature and is looking better and better.There are two competing schools of thought within the incoming US administration that are diametrically opposed on what direction the FDA should take. However, what remains certain is the continued need for robust drug and device development.In contrast to the US, Australia’s, regulatory environment is much more stable. The federal government is highly supportive","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/there-s-more-to-australian-biotech-than-just-csl-the-opportunities-to-watch","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/there-s-more-to-australian-biotech-than-just-csl-the-opportunities-to-watch","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["BK7502","SGXZ23171101.USD","NEU.AU","XKO.AU","LU1169590202.USD","CSL","BK7096","SNT.AU","DXB.AU","BK7511","IMM.AU","BK7501","SG9999004303.SGD","LU1169589451.USD","XAO.AU","BOT.AU","TLX.AU","LU0728928796.USD","OPT.AU","CSL.AU","XJO.AU","BK4086","CVB.AU","BK7007","BK7508","BK7067"],"gpt_icon":0},{"id":"2490840889","title":"Here's Why We're Not At All Concerned With Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2490840889","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490840889?lang=en_us&edition=fundamental","pubTime":"2024-12-11 06:45","pubTimestamp":1733870757,"startTime":"0","endTime":"0","summary":"There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Botanix...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-bot/botanix-pharmaceuticals-shares/news/heres-why-were-not-at-all-concerned-with-botanix-pharmaceuti-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7096","BK7508","BOT.AU","BK7502"],"gpt_icon":0},{"id":"2489440967","title":"5 ways to identify high-quality ASX companies (and 14 stock examples)","url":"https://stock-news.laohu8.com/highlight/detail?id=2489440967","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489440967?lang=en_us&edition=fundamental","pubTime":"2024-12-06 10:49","pubTimestamp":1733453377,"startTime":"0","endTime":"0","summary":"Whenever I ask different fund managers what quality means to them and where quality manifests in the Australian stock market, I get a different response. Yes, there are classic names like CSL and Macquarie Group, but just because a company is large does not make it a high-quality company. Nor is it the case that all small and micro-cap companies are exclusively low-quality... far from it.So, in this wire, I'm testing the concept of \"quality\" and the different qualitative measures that make up a quality stock with the help of Elise Kennedy from Schroders, Andy Forster from Argo Investments, and Kerry Series from NorthStar Impact. Together, they'll each name one stock from each of the following five categories:. \"Why I choose this company is the meaningful free cashflow and the delivery around the OPEX, w","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/5-ways-to-identify-high-quality-asx-companies-and-14-stock-examples","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/5-ways-to-identify-high-quality-asx-companies-and-14-stock-examples","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["BK7135","XRO.AU","BK7126","BK7505","BK7064","BK7041","BK7511","BK7508","CBA.AU","BK7502","AIM.AU","BK7096","BK7153","WES.AU","TNE.AU","BK7017","REH.AU","BOT.AU","SDI.AU","BK7031","BK7016","APZ.AU","BK7042","BK7002","REA.AU","TLS.AU","BK7087","BK7503","BK7097","CAR.AU","SDV.AU","TWE.AU"],"gpt_icon":0},{"id":"2489432650","title":"Investing in a World of Options and Asymmetry","url":"https://stock-news.laohu8.com/highlight/detail?id=2489432650","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489432650?lang=en_us&edition=fundamental","pubTime":"2024-12-05 20:01","pubTimestamp":1733400077,"startTime":"0","endTime":"0","summary":"“The secret to wealth is finding the asymmetric payoff—small risk, big reward” Nassim Taleb. When this writer first set about a career in finance we were tasked with uncovering how much each ASX energy company was worth, with little more direction than a basic understanding of discounted cash flows and net present values. The task was easy enough; to develop an asset by asset model that delivered a valuation per share, but how do you consider:. Specifically when it comes to oil and gas we were utilising it in the pricing of exploration plays. How does this work?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/investing-in-a-world-of-options-and-asymmetry","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/investing-in-a-world-of-options-and-asymmetry","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["BK7503","IE00BDGV0183.EUR","LU0289961442.SGD","LU0289739343.SGD","MTR.AU","LU2477742899.HKD","PET","WTC.AU","BK7507","MTR","CU6.AU","BK4211","BOT.AU","OPC.AU","ASB.AU","AFL.AU","BK7067","IE00BVYPNV92.GBP","BK4162","BK7502","ASB","NEU.AU","AFL","ORA","BK7053","LU0124676726.USD","TLX","LU0472753341.HKD","LU2506952337.HKD","MIN","BK7508","BK7050","IE00B3PB1722.GBP","IMR.AU","AS","LU0689626769.HKD","NEU","ORA.AU","LU0511384066.AUD","IE00B2PGVK34.USD","TAM.AU","BK4133","IE00B3CCJ633.GBP","BK7504","LU2506952410.USD","BK7115","PET.AU","TLX.AU","MIN.AU","BK7096"],"gpt_icon":0},{"id":"2489145700","title":"Botanix Labs' Mission to Bring Bitcoin to Defi Moves to Final Testnet Phase","url":"https://stock-news.laohu8.com/highlight/detail?id=2489145700","media":"CoinDesk","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489145700?lang=en_us&edition=fundamental","pubTime":"2024-12-05 00:25","pubTimestamp":1733329553,"startTime":"0","endTime":"0","summary":"Botanix Labs, the developer of Bitcoin layer-2 network Spiderchain, which aims to advance the possibilities of decentralized finance  on the world's original blockchain, has moved to its final testnet phase ahead of a 2025 mainnet debut.The testnet, known as Aragog, introduces tools that will form the basis for the mainnet's DeFi offering, such as bitcoin -backed stablecoin Palladium, decentralized exchange Bitzy and lending and borrowing market Spindle.Botanix Labs, which aims to introduce the mainnet in the first quarter, is building Spiderchain to be compatible with the Ethereum Virtual Machine , the software that powers the Ethereum network. The goal is to allow any application or smart contract to be copied and pasted onto Bitcoin, creating provision for the kind of DeFi applications that would generally call Ethereum home.In short, Botanix says its aim is to \"bring Bitcoin back online and onchain.\". \"Every member of the Bitcoin economy should work to ensure that demand for onchai","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/botanix-labs-mission-bring-bitcoin-162553915.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["ETHV","BK7508","QETH","BK7502","BTC","BOT.AU","BK4594","FETH","EVM","EZET","CETH","BK4588","BK4601","BK4585","BK7096","BTC.AU"],"gpt_icon":1},{"id":"2485126489","title":"Those who invested in Botanix Pharmaceuticals (ASX:BOT) three years ago are up 443%","url":"https://stock-news.laohu8.com/highlight/detail?id=2485126489","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485126489?lang=en_us&edition=fundamental","pubTime":"2024-11-21 10:49","pubTimestamp":1732157370,"startTime":"0","endTime":"0","summary":"While Botanix Pharmaceuticals Limited  shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 13% in the last quarter. But that doesn't displace its brilliant performance over three years. Indeed, the share price is up a whopping 443% in that time. So you might argue that the recent reduction in the share price is unremarkable in light of the longer term performance. The only way to form a view of whether the current price is justified is to consider the merits of the business itself.So let's investigate and see if the longer term performance of the company has been in line with the underlying business' progress.In the last 3 years Botanix Pharmaceuticals saw its revenue shrink by 24% per year. This is in stark contrast to the strong share price growth of 76%, compound, per year. This clear lack of correlation between revenue and share price is surprising to see in a money losing company. At the risk of upsetting hol","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/TLyt5D16lsSwRjJRVjlUTA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/fd5474a7eee0c5f442903b68fe63249b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/TLyt5D16lsSwRjJRVjlUTA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/fd5474a7eee0c5f442903b68fe63249b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/those-invested-botanix-pharmaceuticals-asx-024930164.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7096","BK7502","BOT.AU","BK7508"],"gpt_icon":0},{"id":"2483385898","title":"Botanix Pharmaceuticals Says US Payer Group to Cover Its Excessive Sweat Medication; Shares Up 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483385898","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483385898?lang=en_us&edition=fundamental","pubTime":"2024-11-14 09:40","pubTimestamp":1731548434,"startTime":"0","endTime":"0","summary":"Botanix Pharmaceuticals  said US payer organization Ascent Health will cover its Sofdra-branded sofpironium topical gel, 12.45%, for the treatment of primary axillary hyperhidrosis, or excessive sweating, according to a Thursday filing with the Australian bourse.Ascent Health is the second largest payer in the US covering 65 million people, the filing said. The company is advancing reimbursement coverage deals with other payers.Botanix Pharmaceuticals' shares rose past 6% in recent Thursday trade.Price : $0.34, Change: $+0.02, Percent Change: +6.25%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7502","BK7508","LU0345774631.USD","LU2238339852.HKD","LU0426412945.USD","LU1043141123.HKD","BOT.AU","LU0426417589.USD","BK7096","AUD","BK4125","LU0994945656.USD"],"gpt_icon":0},{"id":"2480049010","title":"The three-year returns have been enviable for Botanix Pharmaceuticals (ASX:BOT) shareholders despite underlying losses increasing","url":"https://stock-news.laohu8.com/highlight/detail?id=2480049010","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480049010?lang=en_us&edition=fundamental","pubTime":"2024-11-01 06:46","pubTimestamp":1730414792,"startTime":"0","endTime":"0","summary":"Generally speaking, investors are inspired to be stock pickers by the potential to find the big winners. But when you...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-bot/botanix-pharmaceuticals-shares/news/the-three-year-returns-have-been-enviable-for-botanix-pharma","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BOT.AU","BK7502","BK7508","BK7096"],"gpt_icon":0},{"id":"2478999110","title":"Botanix Pharmaceuticals on Track to Launch Patient Experience Program for Sofdra in Q4; Shares Up 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478999110","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478999110?lang=en_us&edition=fundamental","pubTime":"2024-10-28 10:20","pubTimestamp":1730082013,"startTime":"0","endTime":"0","summary":"Botanix Pharmaceuticals  is on track to launch its patient experience program for underarm sweating prescription, Sofdra, in the fourth quarter of the 2024 calendar year, according to a Monday filing with the Australian bourse.The program intends to introduce Sofdra to its first commercial users for initial feedback before being rolled out to larger volumes of patients in the first quarter of 2025.The clinical dermatology company added that it is on pace to generate first prescriptions from the sales in the coming months, followed by first refills.Botanix's shares were up 6% in recent trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7502","BK7096","BOT.AU"],"gpt_icon":0},{"id":"2478561723","title":"Here's Why We're Not At All Concerned With Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2478561723","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478561723?lang=en_us&edition=fundamental","pubTime":"2024-10-25 08:59","pubTimestamp":1729817953,"startTime":"0","endTime":"0","summary":"Just because a business does not make any money, does not mean that the stock will go down. Indeed, Botanix Pharmaceuticals  stock is up 156% in the last year, providing strong gains for shareholders. But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt.So notwithstanding the buoyant share price, we think it's well worth asking whether Botanix Pharmaceuticals' cash burn is too risky. For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. First, we'll determine its cash runway by comparing its cash burn with its cash reserves.Does Botanix Pharmaceuticals Have A Long Cash Runway?","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/TLyt5D16lsSwRjJRVjlUTA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/fd5474a7eee0c5f442903b68fe63249b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/TLyt5D16lsSwRjJRVjlUTA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/fd5474a7eee0c5f442903b68fe63249b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-why-were-not-concerned-005913435.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7508","BK7502","BOT.AU","BK7096"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":34,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BOT.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BOT.AU\",market:\"AU\",,,undefined,":[]}}